Immune checkpoint inhibitor (ICI)

DRUG5 trials

Sponsors

ImmuneSensor Therapeutics Inc., Johns Hopkins University, Stingray Therapeutics, Tongji Hospital, West China Hospital

Conditions

Advanced / Metastatic Solid TumorCutaneous Toxicity From ICI TherapyHead and Neck Squamous Cell CarcinomaHepatocellular CarcinomaSolid Tumor, Adult

Phase 1

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

CompletedNCT04020185

ImmuneSensor Therapeutics Inc.Solid Tumor, Adult

Start: 2019-09-23End: 2023-09-15Updated: 2024-12-11

A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors

RecruitingNCT06063681

Stingray TherapeuticsAdvanced / Metastatic Solid Tumor

Start: 2023-10-12End: 2025-12-31Target: 25Updated: 2025-06-08

Phase 2

Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study

Not yet recruitingNCT07064668

Tongji HospitalHepatocellular Carcinoma

Start: 2025-07-30End: 2027-12-30Target: 300Updated: 2025-07-15

Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC

RecruitingNCT07572864

West China HospitalHead and Neck Squamous Cell Carcinoma

Start: 2026-06-29End: 2028-05-01Target: 9Updated: 2026-08-07

Unknown Phase

Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors

CompletedNCT04898751

Johns Hopkins UniversityCutaneous Toxicity From ICI Therapy

Start: 2008-01-01End: 2020-08-31Updated: 2021-05-24

Related Papers

Abstract CT200: Phase I dose-escalation study of ENPP1 inhibitor, vizenpistat, for the treatment of solid tumors

Cancer Research2026-04-17

Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies

Journal for ImmunoTherapy of Cancer2025-06-019 citations

Abstract CT161: First-in-human study of ENPP1 inhibitor, SR-8541A, for the treatment of solid tumors

Cancer Research2024-04-051 citations

Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study.

2022-05-2020 citations